• REEV secures $9.2 million in funding to advance wearable robotics aimed at assisting individuals with neurological mobility impairments.
  • The funding will support clinical trials, FDA approval efforts, and the development of REEV’s lightweight, personalized mobility solutions.

Medtech startup REEV has raised $9.2 million in a funding round aimed at advancing its wearable robotics technology designed to assist individuals with mobility impairments, particularly those affected by neurological conditions.

The funding round was led by Newfund Heka, Polytechnique Ventures, and Irdi Capital, with additional support from Techstars and a group of business angels and healthcare professionals. Among the notable investors are French soccer player Raphaël Varane and knee surgeon Dr. Hervé Silbert, facilitated by multi-family office Scala Patrimoine.

REEV is developing two key technologies for mobility support:

  • REEV SENSE – A motion sensor system that attaches to a patient’s shoe or leg, providing precise gait analysis.
  • DREEVEN – A wearable robotic system utilizing electro-hydraulic technology to deliver personalized knee assistance.

The company aims to improve upon existing exoskeleton solutions by making devices lighter, more cost-effective, and tailored to individual needs. The first commercial units of DREEVEN are expected to launch in 2026.

Recent milestones for REEV include completing a clinical study at MIT’s Center for Clinical and Translational Research, securing FDA and CE medical certifications for the first 100 commercial units of REEV SENSE, and testing functional DREEVEN prototypes on individuals with gait disorders.

The newly secured funding will support the miniaturization and industrialization of DREEVEN, as well as a pivotal clinical study at Boston University’s Neuromotor Recovery Lab, led by Dr. Lou Awad. The company is also preparing for large-scale U.S. trials to seek FDA clearance.

"With the support of our world-class partners, we are thrilled to enter the next phase of clinical and industrial development," said Amaury Ciurana, Co-Founder and CEO of REEV.
"Our innovative technologies, like the DREEVEN motorized orthosis, aim to redefine mobility assistance, transforming lives and reshaping the orthotics industry."

Investors view the funding as a step toward expanding mobility solutions. “We are proud to continue supporting REEV as they work toward FDA clearance to bring their technology to market in the U.S. This marks a key milestone in improving mobility for neurological patients,” said Anne-Sophie Saint-Martin, Partner at Newfund.

With its latest funding and ongoing clinical studies, REEV is positioning itself to advance wearable robotics in the healthcare sector, potentially offering a new standard for mobility support.

Edited by Harshajit Sarmah